1 / 9

HOXA9 and its Role in Acute Myeloid Leukemia

HOXA9 and its Role in Acute Myeloid Leukemia. Brent Hoffman. HOXA9 is one of the HOX transcription factors regulating Anterior to Posterior patterning in early development. HOXA9 regulates bone marrow stem cell proliferation and cells differentiate as HOXA9 expression decreases.

bin
Download Presentation

HOXA9 and its Role in Acute Myeloid Leukemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HOXA9 and its Role in Acute Myeloid Leukemia Brent Hoffman

  2. HOXA9 is one of the HOX transcription factors regulating Anterior to Posterior patterning in early development

  3. HOXA9 regulates bone marrow stem cell proliferation and cells differentiate as HOXA9 expression decreases

  4. HOXA9 -/- bone marrow cells showed inhibited ability to repopulate in vitro after hematopoietic stress

  5. Acute Myeloid Leukemia is a cancer of the bone marrow affecting white blood cell proliferation and differentiation

  6. In AML, a translocation joinsHOXA9 to NUP98

  7. Fusion of the NUP98 gene to HOXA9 induces AML in mice cells

  8. Current treatment for AML is divided into two phases: remission induction and post-remission therapy

  9. References • “Acute Myelogenous Leukemia (AML).” Mayoclinic. Mayo Clinic Staff, 5 Sept. 2012. Web. 4-4/13. <http://www.mayoclinic.com/health/acute-myelogenous-leukemia/DS00548/DSECTION=treatments-and-drugs>. • “Acute Myelogenous Leukemia.” Cleveland Clinic. Web. 4–11 2013. <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/>. • “Adult Acute Myeloid Leukemia Treatment (PDQ®).” National Cancer Institute . Web. 11–4 2012. <http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/Patient/page3>. • “Algorithmic and Topological Body Plans.” Web. 11–4 2012. <http://www.19thpsalm.org/Ch09/Algorithm-Topology.html>. • Gough, S. M., Slape, C. L., & Aplan, P. D. (2011). NUP98 gene fusions and hematopoietic and new biologic insights malignancies: common themes . Blood, 118(24), 6247–6257. Retrieved from http://bloodjournal.hematologylibrary.org/content/118/24/6247.full.pdf+html • Hematopoeisis from Multipotent Stem Cells. (2012). Retrieved from http://www.ebioscience.com/resources/pathways/hematopoiesis-from-multipotent-stem-cells.htm • “Hematopoietic Stem Cell Transplantation (HSCT) and Cerebral ALD.” Web. 4–11 2013. <http://www.x-ald.nl/treatment-options/hsct/>. • Kroon, Evert et al. “NUP98–HOXA9 Expression in Hemopoietic Stem Cells Induces Chronic and Acute Myeloid Leukemias in Mice.” The EMBO Journal 20.3 (2001): 350–361. NCBI. Web. 4–11 2013. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC133485/>. • Lawrence, Jeffrey H et al. “Loss of Expression of the Hoxa-9 Homeobox Gene Impairs the Proliferation and Repopulating Ability of Hematopoietic Stem Cells.” Blood 106.12 (2005): 3988–3994. Print. • “Typical Treatment of Acute Myeloid Leukemia (except Promyelocytic M3).” American Cancer Society. Web. 11-4/13. <http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-treating-typical-treatment-of-aml>.

More Related